Literature DB >> 20647335

Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.

Min Yi1, Kelly K Hunt, Banu K Arun, Isabelle Bedrosian, Angelica Gutierrez Barrera, Kim-Anh Do, Henry M Kuerer, Gildy V Babiera, Elizabeth A Mittendorf, Kaylene Ready, Jennifer Litton, Funda Meric-Bernstam.   

Abstract

Increasing numbers of women with breast cancer are electing for contralateral prophylactic mastectomy (CPM) to reduce the risk of developing contralateral breast cancer. The objective of this study was to identify factors that may affect a patient's decision to undergo CPM. We identified 2,504 women with stage 0 to III unilateral primary breast cancer who underwent breast surgery at our institution from January 2000 to August 2006 from a prospectively maintained database. We did logistic regression analyses to determine which factors were associated with undergoing CPM. Of 2,504 breast cancer patients, 1,223 (48.8%) underwent total mastectomy. Of the 1,223 patients who underwent mastectomy, 284 (23.2%) underwent immediate or delayed CPM. There were 33 patients (1.3%) who had genetic testing before the surgery, with the use of testing increasing in the latter years of the study (0.1% in 2000-2002 versus 2.0% in 2003-2006; P < 0.0001). Multivariable analysis revealed several factors that were associated with a patient undergoing CPM: age younger than 50 years, white ethnicity, family history of breast cancer, BRCA1/2 mutation testing, invasive lobular histology, clinical stage, and use of reconstruction. We identified specific patient and tumor characteristics associated with the use of CPM. Although genetic testing is increasing, most women undergoing CPM did not have a known genetic predisposition to breast cancer. Evidence-driven models are needed to better inform women of their absolute risk of contralateral breast cancer as well as their competing risk of recurrence from the primary breast cancer to empower them in their active decision making. 2010 AACR.

Entities:  

Mesh:

Year:  2010        PMID: 20647335      PMCID: PMC4340054          DOI: 10.1158/1940-6207.CAPR-09-0130

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  34 in total

1.  Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma.

Authors:  Thao N Vo; Funda Meric-Bernstam; Min Yi; Thomas A Buchholz; Frederick C Ames; Henry M Kuerer; Isabelle Bedrosian; Kelly K Hunt
Journal:  Am J Surg       Date:  2006-10       Impact factor: 2.565

2.  The evolving role of MRI in the detection and evaluation of breast cancer.

Authors:  Robert A Smith
Journal:  N Engl J Med       Date:  2007-03-28       Impact factor: 91.245

3.  Clinical and histological predictors of contralateral breast cancer.

Authors:  J Kollias; I O Ellis; C W Elston; R W Blamey
Journal:  Eur J Surg Oncol       Date:  1999-12       Impact factor: 4.424

4.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

5.  Selective use of sentinel lymph node surgery during prophylactic mastectomy.

Authors:  Judy C Boughey; Nazanin Khakpour; Funda Meric-Bernstam; Merrick I Ross; Henry M Kuerer; Sonja E Singletary; Gildy V Babiera; Banu Arun; Kelly K Hunt; Isabelle Bedrosian
Journal:  Cancer       Date:  2006-10-01       Impact factor: 6.860

6.  Predictors of breast conservation therapy: size is not all that matters.

Authors:  Karen Hiotis; Wei Ye; Richard Sposto; Kristin A Skinner
Journal:  Cancer       Date:  2005-03-01       Impact factor: 6.860

7.  Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy.

Authors:  Min Yi; Funda Meric-Bernstam; Lavinia P Middleton; Banu K Arun; Isabelle Bedrosian; Gildy V Babiera; Rosa F Hwang; Henry M Kuerer; Wei Yang; Kelly K Hunt
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

8.  MRI of occult breast carcinoma in a high-risk population.

Authors:  Elizabeth A Morris; Laura Liberman; Douglas J Ballon; Mark Robson; Andrea F Abramson; Alexandra Heerdt; D David Dershaw
Journal:  AJR Am J Roentgenol       Date:  2003-09       Impact factor: 3.959

Review 9.  Contralateral prophylactic mastectomy for patients with unilateral breast cancer.

Authors:  Todd Tuttle; Elizabeth Habermann; Anasooya Abraham; Timothy Emory; Beth Virnig
Journal:  Expert Rev Anticancer Ther       Date:  2007-08       Impact factor: 4.512

10.  Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ.

Authors:  Todd M Tuttle; Stephanie Jarosek; Elizabeth B Habermann; Amanda Arrington; Anasooya Abraham; Todd J Morris; Beth A Virnig
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

View more
  49 in total

1.  Triple-negative breast cancer is not a contraindication for breast conservation.

Authors:  Farrell C Adkins; Ana Maria Gonzalez-Angulo; Xiudong Lei; Leonel F Hernandez-Aya; Elizabeth A Mittendorf; Jennifer K Litton; Jamie Wagner; Kelly K Hunt; Wendy A Woodward; Funda Meric-Bernstam
Journal:  Ann Surg Oncol       Date:  2011-09-27       Impact factor: 5.344

2.  Surgical Management of Lobular Carcinoma In Situ: Analysis of the National Cancer Database.

Authors:  Lauren J Taylor; Jennifer Steiman; Jessica R Schumacher; Lee G Wilke; Caprice C Greenberg; Heather B Neuman
Journal:  Ann Surg Oncol       Date:  2018-05-31       Impact factor: 5.344

3.  Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer.

Authors:  Shoshana M Rosenberg; Karen Sepucha; Kathryn J Ruddy; Rulla M Tamimi; Shari Gelber; Meghan E Meyer; Lidia Schapira; Steven E Come; Virginia F Borges; Mehra Golshan; Eric P Winer; Ann H Partridge
Journal:  Ann Surg Oncol       Date:  2015-05-01       Impact factor: 5.344

Review 4.  Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis.

Authors:  Oluwadamilola Motunaryo Fayanju; Carolyn R T Stoll; Susan Fowler; Graham A Colditz; Julie A Margenthaler
Journal:  Ann Surg       Date:  2014-12       Impact factor: 12.969

Review 5.  Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer.

Authors:  Abenaa M Brewster; Patricia A Parker
Journal:  Oncologist       Date:  2011-06-14

6.  Social and Clinical Determinants of Contralateral Prophylactic Mastectomy.

Authors:  Sarah T Hawley; Reshma Jagsi; Monica Morrow; Nancy K Janz; Ann Hamilton; John J Graff; Steven J Katz
Journal:  JAMA Surg       Date:  2014-06       Impact factor: 14.766

7.  Contralateral prophylactic mastectomy in young women with breast cancer: a population-based analysis of predictive factors and clinical impact.

Authors:  A Bouchard-Fortier; N N Baxter; R Sutradhar; K Fernandes; X Camacho; P Graham; M L Quan
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

8.  Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer.

Authors:  Leila Green; Funda Meric-Bernstam
Journal:  Curr Breast Cancer Rep       Date:  2011-09-01

9.  Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.

Authors:  Shoshana M Rosenberg; Michaela S Tracy; Meghan E Meyer; Karen Sepucha; Shari Gelber; Judi Hirshfield-Bartek; Susan Troyan; Monica Morrow; Lidia Schapira; Steven E Come; Eric P Winer; Ann H Partridge
Journal:  Ann Intern Med       Date:  2013-09-17       Impact factor: 25.391

10.  Cost of contralateral prophylactic mastectomy.

Authors:  Ashish A Deshmukh; Scott B Cantor; Melissa A Crosby; Wenli Dong; Yu Shen; Isabelle Bedrosian; Susan K Peterson; Patricia A Parker; Abenaa M Brewster
Journal:  Ann Surg Oncol       Date:  2014-05-09       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.